PTHS
Pelthos Therapeutics Inc.
US
Income statement
| Metric | TTM | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | 7.4M | — | — | — |
| Cost of Revenue | 3.4M | — | — | — |
| Gross Profit | 4.0M | — | — | — |
| Operating Expenses | ||||
| R&D Expense | 1.1M | 1.2M | 2.6M | 391.7K |
| SG&A Expense | 25.1M | 6.4M | 4.3M | 1.9M |
| General & Admin Expense | 5.9M | 6.4M | 4.3M | 1.9M |
| Selling & Marketing Expense | — | — | — | — |
| Other Expenses | — | — | — | — |
| Total Operating Expenses | 26.3M | 7.6M | 6.9M | 2.3M |
| Cost and Expenses | 29.7M | 7.6M | 6.9M | 2.3M |
| Operating Income (EBIT) | (22.3M) | (7.6M) | (6.9M) | (2.3M) |
| Non-Operating | ||||
| Interest Income | 5.0K | — | — | — |
| Interest Expense | 1.8M | 786.4K | 518.5K | 140.4K |
| Net Interest Income | (1.8M) | (786.4K) | (518.5K) | (140.4K) |
| Other Non-Op Income/Expense | (1.8M) | (383.9K) | (518.5K) | (140.4K) |
| Non-Operating Income (excl Interest) | (11.3K) | (402.5K) | — | — |
| EBT (Pre-Tax Income) | (24.0M) | (8.0M) | (7.4M) | (2.5M) |
| Income Tax Expense | (465.0K) | — | — | — |
| Bottom Line | ||||
| Net Income | (23.6M) | (8.0M) | (7.4M) | (2.5M) |
| Earnings from Cont. Ops | (23.6M) | (8.0M) | (7.4M) | (2.5M) |
| Earnings from Discont. Ops | — | — | — | — |
| Bottom Line Net Income | (23.6M) | (8.0M) | (7.4M) | (2.5M) |
| Per Share | ||||
| Basic EPS | ($37.16) | ($13.54) | ($12.80) | ($4.26) |
| Diluted EPS | ($37.16) | ($13.54) | ($12.80) | ($4.26) |
| Revenue Per Share | $11.56 | $0.00 | $0.00 | $0.00 |
| Shares | ||||
| Basic Shares Outstanding | 640518 | 587620 | 576752 | 576752 |
| Diluted Shares Outstanding | 640518 | 587620 | 576752 | 576752 |
| Profitability Metrics | ||||
| EBITDA | (21.1M) | (7.2M) | (6.9M) | (2.3M) |
| D&A | 1.1M | — | — | — |
| EBIT | (22.2M) | (7.2M) | (6.9M) | (2.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025